TY - JOUR
T1 - Overcoming Therapeutic Resistance of Bone Sarcomas
T2 - Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells
AU - Fujiwara, Tomohiro
AU - Ozaki, Toshifumi
N1 - Publisher Copyright:
© 2016 Tomohiro Fujiwara and Toshifumi Ozaki.
PY - 2016
Y1 - 2016
N2 - Bone sarcomas are heterogeneous malignant tumors that exhibit clinical, histological, and molecular heterogeneity. Recent progress in their multimodal treatment has gradually improved patient prognosis; however, drug resistance and distant metastasis remain unresolved clinical problems. Recent investigations have suggested the existence of cancer stem-like cells (CSCs) in bone sarcomas, which represent a subpopulation of tumor cells with high tumor-forming ability. The hallmarks of CSCs include tumor-and metastasis-forming potential and drug resistance, which are responsible for poor prognoses of bone sarcoma patients. Therefore, elucidation of the molecular mechanisms of CSCs and identification of therapeutic targets could contribute to novel treatment strategies for bone sarcomas and improve patient prognosis. This paper provides an overview of the accumulating knowledge on bone sarcoma stem cells and preclinical analyses to overcome their lethal phenotypes, in addition to a discussion of their potential for novel therapeutics for bone sarcomas.
AB - Bone sarcomas are heterogeneous malignant tumors that exhibit clinical, histological, and molecular heterogeneity. Recent progress in their multimodal treatment has gradually improved patient prognosis; however, drug resistance and distant metastasis remain unresolved clinical problems. Recent investigations have suggested the existence of cancer stem-like cells (CSCs) in bone sarcomas, which represent a subpopulation of tumor cells with high tumor-forming ability. The hallmarks of CSCs include tumor-and metastasis-forming potential and drug resistance, which are responsible for poor prognoses of bone sarcoma patients. Therefore, elucidation of the molecular mechanisms of CSCs and identification of therapeutic targets could contribute to novel treatment strategies for bone sarcomas and improve patient prognosis. This paper provides an overview of the accumulating knowledge on bone sarcoma stem cells and preclinical analyses to overcome their lethal phenotypes, in addition to a discussion of their potential for novel therapeutics for bone sarcomas.
UR - http://www.scopus.com/inward/record.url?scp=85009413856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009413856&partnerID=8YFLogxK
U2 - 10.1155/2016/2603092
DO - 10.1155/2016/2603092
M3 - Review article
AN - SCOPUS:85009413856
SN - 1687-9678
VL - 2016
JO - Stem Cells International
JF - Stem Cells International
M1 - 2603092
ER -